BCYC
$4.35-0.20 (-4.40%)
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Recent News
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Drop Over 2% for Week
European equities traded in the US as American depositary receipts were sharply lower late Friday mo
European Equities Traded in US as ADRs Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell late Wednesday morning with
Bicycle Therapeutics (BCYC) Appoints Travis Thompson as CFO Following Leadership Transitions
Bicycle Therapeutics (NASDAQ:BCYC) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 3, Bicycle Therapeutics announced several key leadership transitions as the company enters a new phase of innovation for its proprietary bicyclic peptide technology. Travis Thompson, who joined the firm in 2018 and previously served as senior vice […]
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were lower late Friday morning, d
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower late